Cargando…
Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
Triple-negative breast cancer (TNBC) shows a higher malignant and poorer clinical outcome compared with other breast cancer subtypes. Albeit that chemotherapy is the first choice for TNBC treatment, rapid emergence of chemoresistance and variability of chemotherapeutic responses in TNBC patients cal...
Autores principales: | Li, Haolong, Liu, Lei, Chang, Haocai, Zou, Zhengzhi, Xing, Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833778/ https://www.ncbi.nlm.nih.gov/pubmed/29374168 http://dx.doi.org/10.1038/s41419-017-0169-2 |
Ejemplares similares
-
Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020) -
Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016) -
First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015) -
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018) -
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)